Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Headwaters Capital Christopher Godfrey | “Bio-Techne: Coveted Life Sciences Asset On Sale Due to Academic Pressures Summary Thesis: 1) Market leading life sciences reagents and instrument company. Recurring consumable revenue, strong profit margins, healthy free cash flow and a net cash position. 2) Concern around US academic funding is weighing on shares of TECH, pressuring the stock to its lowest valuation since 2017. 3) Revenue growth rate inflecting higher in FY '27 (6/30 FYE) as Company laps one-time NIH budget reset and growth assets propel consolidated revenue. 4) Coveted asset as evidenced by recent M&A transactions, which supports a significantly higher valuation than implied by current share price. Bio-Techne (“TECH”) develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. Founded in 1976 as Research and Diagnostic Systems, the company IPO'd in 1985 when it merged with Techne Corporation. TECH has been a leader in manufacturing high-quality antibodies and proteins used in life sciences research. The Company also manufactures instruments that utilize these reagents, creating a razor/razor blade model. In 2013, the Company embarked on a strategy to accelerate revenue growth by utilizing cash flow from its Protein Sciences business to acquire growth assets. Protein Sciences – TECH's Crown Jewel Protein Sciences represents the original TECH business that sells reagents and instruments into research and diagnostics markets. Key customers in this segment include research institutions, biopharma, pharma and diagnostics companies. TECH's proteins and antibodies are widely used in academic research, which in addition to patent and trademark protection, provides important validation for the quality of the products. Academic citations also serve as a strong marketing tool for TECH's products and help to drive future sales. On the equipment side, TECH's growing installed base of instruments provides visibility into ongoing utilization of TECH's products. More recently, TECH has broadened its customer base and now sells GMP grade proteins that are utilized in the production of cell and gene therapies (“C>”), both in clinical trials and FDA approved commercial products. The C> business represents a growth opportunity for the segment as clinical trial customers (85 today) ultimately convert to commercial customers (4 today). The core reagents and instruments business has historically grown at mid to high single digit rate as ongoing innovation in drug discovery and development has fueled strong demand for TECH's products. While comprising only ~11% of Protein Sciences revenue today, TECH's emerging C> business is projected to sustain its +20% growth rate over the next few years, supporting ongoing growth for this segment. Gross margins for the Protein Sciences segment are ~75% and the business generates an impressive 45% operating margin. The Protein Sciences segment accounts for ~70...ed operating income. This is the crown jewel of Bio-Techne. Diagnostics and Genomics – TECH's Venture Capital Portfolio TECH's Diagnostics and Genomics business represents a collection of assets that have been acquired since the 2013 strategy shift. Many of these businesses are small and each one specializes in niche diagnostic and research markets. Key areas of focus include spatial biology, liquid biopsy, molecular diagnostics and diagnostic reagents. ... its bets in these markets and that the portfolio will ultimately deliver shareholder value. Investment Opportunity – Customer Budget Concerns TECH's stock has been hit hard by concerns around cuts to NIH/NSF funding, which will have a direct impact on the 12% of TECH's revs that are generated from US academic customers. As proposed today, the 2026 fiscal budget would cut the NIH budget by 40%. TECH's revenues should be less exposed to the full 40% cut for a myriad of reasons (less indirect cost exposure, consummables focus, priority funding areas, etc), but this figure is a good baseline to run sensitivity analysis around NIH exposure. TECH also has risks related to China revenue (8% of revs) and general uncertainty around pharma and biopharma spending. N...FY '26 (6/30/26 YE). This uncertainty has weighed on not only TECH's stock, but also the broader healthcare sector and life sciences tools industry. While the chart below illustrates Healthcare's underperformance for large caps, the same dynamic is occurring in small caps. As a result of the pressure on the healthcare sector broadly as well as specific risks to TECH's revenues, the Company's shares traded down to a multiple not seen since 2017. While the absolute multiple by itself is likely at or near a floor, it was interesting that TECH's multiple also approached that of Thermo Fisher (“TMO”). TMO has always been considered a natural acquirer given that TECH already has a commercial distribution agreement with Thermo in its Protein Sciences segment. Additionally, TECH's CEO, CFO and President of Protein Sciences all held previous roles at TMO. As can be seen below, TECH's shares have historically traded at a premium to TMO given faster revenue growth rates and an embedded take-out premium (from TMO or any other larger cap player). This provides some comfort that shares of TECH are likely at or near a trough valuation. BSD Analysis: Bio-Techne is a life-sciences supplier that sells critical reagents, tools, and diagnostics used throughout biological research and bioprocessing. Its portfolio benefits from recurring demand across academia, pharma, and biomanufacturing. The company has been expanding into higher-margin, clinically oriented diagnostics and advanced analytics. Biotech funding cycles affect sentiment, but underlying consumable demand is resilient. Acquisitions remain a core part of the strategy, and integration has been strong historically. Margins should improve as bioprocessing grows as a share of revenue. Bio-Techne remains a diversified, high-quality picks-and-shovels name.” | BULL | Q2 2025 Jul 10, 2025 | View Pitch |
Alger Small Cap Focus Fund Amy Zhang | “Bio-Techne is a leading provider of essential life science products, including reagents (such as proteins), analytical instruments, and related services. Its products are primarily used by customers in biopharmaceutical companies, academic and government research institutions, and clinical laboratories to support drug development, advanced scientific research, and innovative diagnostic techniques. Shares of Bio-Techne detracted from performance in the second quarter after the company delivered solid fiscal third-quarter results but lowered its guidance for the fiscal fourth quarter, citing challenging macroeconomic conditions. Management highlighted near-term concerns related to uncertainty over global tariffs, constraints on academic research funding, and pressures on drug pricing, all of which could temporarily weaken demand. However, despite these short-term challenges, we maintain a favorable view of the company's long-term fundamentals, driven by its innovative product portfolio, experienced management team, and strong underlying business model. BSD Analysis: Bio-Techne is the research-tools powerhouse quietly embedded in every corner of biotech, proteomics, and cell therapy. Its reagents, proteins, and instruments are high-margin, high-recurrence products that labs can't easily switch away from. Growth slowed with the biotech funding downturn, but Bio-Techne's product breadth and innovation pipeline give it leverage once capital flows normalize. The company is diversified across diagnostics, life sciences, and bioprocessing, providing stability in volatile cycles. Bio-Techne isn't a hype-driven biotech — it's the picks-and-shovels supplier with structural demand. When R&D spending rebounds, margins and revenue should re-accelerate sharply.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
